Summary: In this presentation, Andy Nicholls, Head of Data Science within GSK Biostatistics, provided an overview of GSK’s WARP environment for Biostatistics. The presentation described the key requirements that led to building the environment and included an overview of the basic technical components that enabled these requirements. Nicholls also discussed GSK support and maintenance strategy for R and R packages.
The presentation touched upon important topics that fed into the discussion:
Support and maintenance strategy for R
Controlled execution of R (GxP workflows)
In-house vs cloud infrastructure
Intro – 10 mins
Case Study presentation: Scaling R at GSK – 45 mins (including 10 mins for Q&A)
Break – 5 mins
Parallel discussions – 45 mins
Andy Nicholls is Head of Data Science within GSK Biostatistics. He has been a user and strong advocate for the use of R for over 15 years. Andy is responsible for driving the R adoption initiative within GSK Biostatistics. His team helped create Biostatistics’ first dedicated analytics platform for R and developed a world-wide R training programming. The team has also led the development of several R-based tools and applications to assist the rollout and adoption of R as a clinical and non-clinical reporting capability. Within the wider industry, Andy is the lead for the R Validation Hub, a collaboration to support the adoption of R within a biopharmaceutical regulation setting.
Andy has an MMath degree from University of Bath and MSc Statistics with Applications in Medicine from University of Southampton. Prior to re-joining GSK in 2017 Andy was the Head of Data Science Consultancy at Mango Solutions.
GSK providing COVID era leadership, helping adoption of R Language as standard tool for pharmaceutical industry
SAN FRANCISCO, May 4, 2021 – The R Consortium, a Linux Foundation project supporting the R Foundation and worldwide R community, today announced that GlaxoSmithKline (GSK) has joined as a Silver Member. GSK is a multinational pharmaceutical company headquartered in London, England. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health.
“R is not just an alternative programming language. Through Rmarkdown and Shiny it has the potential to fundamentally change the way we report and share information within the industry. It will help us make better decisions, faster; to the benefit of patients everywhere. We have been actively contributing to the R Consortium Working Groups for quite some time and joining the R Consortium recognises the important role that the R Consortium has to play in shaping the future of R within the pharmaceutical industry,” said Andy Nicholls, Senior Director, Head of Statistical Data Sciences at GSK. “Joining as a Silver member shows our commitment to build a strong R Language infrastructure.”
“We have worked directly with GSK through the R Consortium Working Groups, and having GSK join the R Consortium as a Silver member is an exciting step forward that will positively impact how the R Language advances in the pharmaceutical sector,” said Joseph Rickert, RStudio’s R Community Ambassador and R Consortium Board Chair. “GSK leadership will help data analysis and visualization in the medical field immensely.”
The R Consortium has multiple separate Working Groups focused on pharmaceutical issues: RTRS (Tables), R Submissions (IT), Validation, and more. Participation in R Consortium Working Groups in the pharmaceutical space by GSK will help continue to expand their reach. The Working Groups add value to member companies by initiating and cultivating industry-wide collaborative projects. This is critical in the pharmaceutical industry, providing a framework for competitors to come together and cooperate under an open governance framework to build infrastructure at low-cost. To find out how you can join an R Consortium Working Group, see https://www.r-consortium.org/projects/isc-working-groups
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
About The R Consortium
The R Consortium is a 501(c)6 nonprofit organization and Linux Foundation project dedicated to the support and growth of the R user community. The R Consortium provides support to the R Foundation and to the greater R Community for projects that assist R package developers, provide documentation and training, facilitate the growth of the R Community and promote the use of the R language. For more information about R Consortium, please visit: http://www.r-consortium.org.
About Linux Foundation
Founded in 2000, the Linux Foundation is supported by more than 1,000 members and is the world’s leading home for collaboration on open source software, open standards, open data, and open hardware. Linux Foundation projects like Linux, Kubernetes, Node.js and more are considered critical to the development of the world’s most important infrastructure. Its development methodology leverages established best practices and addresses the needs of contributors, users and solution providers to create sustainable models for open collaboration. For more information, please visit us at linuxfoundation.org